The prognostic value of quantitative parameters of 18F-FDG PET/CT in the evaluation of response to internal radiation therapy with yttrium-90 in patients with liver metastases of colorectal cancer

被引:23
作者
Soydal, Cigdem [1 ]
Kucuk, Ozlem N. [1 ]
Gecim, Ibrahim Ethem [2 ]
Bilgic, Sadik [3 ]
Elhan, Atilla H. [4 ]
机构
[1] Ankara Univ, Fac Med, Dept Nucl Med, TR-06590 Ankara, Turkey
[2] Ankara Univ, Fac Med, Dept Surg, TR-06590 Ankara, Turkey
[3] Ankara Univ, Fac Med, Dept Radiol, TR-06590 Ankara, Turkey
[4] Ankara Univ, Fac Med, Dept Biostat, TR-06590 Ankara, Turkey
关键词
colorectal cancer; liver metastases; selective internal radiation therapy; HEPATOCELLULAR-CARCINOMA; HEPATIC METASTASES; GLASS MICROSPHERES; PLUS CHEMOTHERAPY; RADIOEMBOLIZATION; TRIAL; EXPERIENCE; TUMORS; SIRT;
D O I
10.1097/MNM.0b013e32835f9427
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Introduction The aim of this study was to evaluate tumor response using fluorine-18-fluorodeoxyglucose (F-18-FDG) positron emission tomography/computed tomography (PET/CT) in patients who received yttrium-90 selective internal radiation therapy (SIRT) for colorectal liver metastases. The initial and sixth-week tumor lesion glycolysis values were calculated to evaluate the success of the treatment and compare it with patient survival. Materials and methods Thirty-five patients (15 female, 20 male, mean age: 61.9 +/- 9.0 years, range: 33-76 years) who received SIRT treatment for unresectable colorectal cancer liver metastases in our hospital between June 2008 and May 2011 were included in the study. All patients included in the study had liver-only or liver-dominant disease. The treatment response was evaluated by F-18-FDG PET/CT in the sixth week after treatment. Response was evaluated according to the change in total lesion glycolysis (Delta TLG). The Delta TLG was calculated using the following formula: Delta TLG=100 x [standardized uptake value (SUV)(mean1) x total functional tumor volumes (FTVs)(1) - SUVmean2 x FTV2]/SUVmean1 x FTV1. Results Mean FTV1 and FTV2 values were calculated to be 235.7 +/- 203 and 107.3 +/- 67mm(3), respectively (P=0.04). The mean Delta TLG was 43 +/- 35 (range: 0-100). Mean overall survival time was 12.7 +/- 8.0 months (range: 3-31 months). The cutoff value of Delta TLG was calculated to be 26.5 using receiver operating characteristic analysis (sensitivity 64%; specificity 85%; AUC=0.717 +/- 0.087, P=0.034). Patients were allocated into those having values greater than the cutoff value (group 1) and those having values lower than the cutoff value (group 2) in order to calculate the effect of Delta TLG on survival. Survival was 11.32 +/- 1.18(95% CI 9.02-13.62) months in group 2 and 20.76 +/- 2.71 (95% CI 15.46-26.06) months in group 1 (P=0.016). Delta TLG was found to be a significant factor in univariate analysis (P=0.01). Conclusion An F-18-FDG PET/CT scan with calculation of Delta SUVmax, Delta FTV, and Delta TLG before and at the sixth week after SIRT may play an important role in evaluating early tumor response and survival expectancy in these patients and help decide whether these patients should be referred to other treatment modalities or to follow-up. Nucl Med Commun 34:501-506 (C) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
引用
收藏
页码:501 / 506
页数:6
相关论文
共 25 条
[1]  
Abdalla EK, 2004, ANN SURG, V239, P818, DOI 10.1097/01.sla.0000128305.90650.71
[2]   GLASS Y-90 MICROSPHERES FOR PATIENTS WITH COLORECTAL LIVER METASTASES [J].
ANDERSON, JH ;
GOLDBERG, JA ;
BESSENT, RG ;
KERR, DJ ;
MCKILLOP, JH ;
STEWART, I ;
COOKE, TG ;
MCARDLE, CS .
RADIOTHERAPY AND ONCOLOGY, 1992, 25 (02) :137-139
[3]  
ANDREWS JC, 1994, J NUCL MED, V35, P1637
[4]   90Y microsphere treatment of unresectable liver metastases:: changes in 18F-FDG uptake and tumour size on PET/CT [J].
Bienert, M ;
McCook, B ;
Carr, BI ;
Geller, DA ;
Sheetz, M ;
Tutor, C ;
Amesur, N ;
Avril, N .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 (07) :778-787
[5]  
BLANCHARD RJW, 1989, J CAN ASSOC RADIOL, V40, P206
[6]   Randomised trial of SIR-Spheres® plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer [J].
Gray, B ;
Van Hazel, G ;
Hope, M ;
Burton, M ;
Moroz, P ;
Anderson, J ;
Gebski, V .
ANNALS OF ONCOLOGY, 2001, 12 (12) :1711-1720
[7]   The prognostic value of functional tumor volume and total lesion glycolysis in patients with colorectal cancer liver metastases undergoing 90Y selective internal radiation therapy plus chemotherapy [J].
Gulec, Seza A. ;
Suthar, Rekha R. ;
Barot, Tushar C. ;
Pennington, Kenneth .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 (07) :1289-1295
[8]   A METHOD OF COMPARING THE AREAS UNDER RECEIVER OPERATING CHARACTERISTIC CURVES DERIVED FROM THE SAME CASES [J].
HANLEY, JA ;
MCNEIL, BJ .
RADIOLOGY, 1983, 148 (03) :839-843
[9]   Radioembolization for hepatic metastases [J].
Herba, MJ ;
Thirlwell, MP .
SEMINARS IN ONCOLOGY, 2002, 29 (02) :152-159
[10]   HEPATOCELLULAR-CARCINOMA - PILOT TRIAL OF TREATMENT WITH Y-90 MICROSPHERES [J].
HOULE, S ;
YIP, TCK ;
SHEPHERD, FA ;
ROTSTEIN, LE ;
SNIDERMAN, KW ;
THEIS, E ;
CAWTHORN, RH ;
RICHMONDCOX, K .
RADIOLOGY, 1989, 172 (03) :857-860